| Symbol | NPHC |
|---|---|
| Name | NUTRA PHARMA CORP. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 33313 United States FL 1537 NW 65th Avenue |
| Telephone | (954) 509-0911 |
| Fax | — |
| — | |
| Website | http://www.nutrapharma.com |
| Incorporation | US |
| Incorporated On | 2000 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Marcum LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001119643 |
| Description | Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brands Nyloxin, Pet Pain-Away, Equine Pain-Away and Luxury Feet.. Additional info from OTC: |
No news found.